Home » Stocks » ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Stock Price: $128.78 USD -2.52 (-1.92%)
Updated May 10, 2021 1:56 PM EDT - Market open
Market Cap 15.43B
Revenue (ttm) 570.94M
Net Income (ttm) -876.35M
Shares Out 117.08M
EPS (ttm) -7.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $128.78
Previous Close $131.30
Change ($) -2.52
Change (%) -1.92%
Day's Open 131.28
Day's Range 128.08 - 130.63
Day's Volume 123,921
52-Week Range 119.29 - 178.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following co...

6 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-mo...

1 week ago - Business Wire

Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.

1 week ago - Zacks Investment Research

Alnylam (ALNY) delivered earnings and revenue surprises of 2.29% and 0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Marc...

1 week ago - Business Wire

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisira...

3 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending...

3 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of ALN-AGT...

4 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 20th Annual...

1 month ago - Business Wire

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). The results ...

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal trial results from the ILLUMINATE-A Phase 3 study of ...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 3rd ...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 9-month results from the HELIOS...

1 month ago - Business Wire

Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136)....

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today issued its first Corporate Responsibility (CR) Summary, formalizing the mana...

1 month ago - Business Wire

FRISCO, Texas--(BUSINESS WIRE)-- #soleohealhtotreatAHPwithGIVLAARI--Soleo Health to Administer Alnylam Pharmaceuticals' GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following co...

2 months ago - Business Wire

With the trading day more than halfway over, the broad markets could not make up their mind on a direction.

Other stocks mentioned: FL, NVDA, PBR, PBR.A, DAL, BBIO, FREE ...
2 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 10th Annual...

2 months ago - Business Wire

Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.

2 months ago - Zacks Investment Research

Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 19.19% over the past year to ($1.60), which beat the ...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full ...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and y...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Company's p...

4 months ago - Business Wire

Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints. Vutrisiran's improved dosing profile and tolerability are ...

4 months ago - Seeking Alpha

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational ...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annual...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial ...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Compan...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Inv...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new reports: the second annual update on its Patient Access Ph...

5 months ago - Business Wire

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C P...

5 months ago - Business Wire

The company's rare disease treatments are a huge success and there will probably be a lot more of them.

5 months ago - The Motley Fool

The company's rare disease treatments are a huge success and there will probably be a lot more of them.

5 months ago - The Motley Fool

Revenue is growing at a high percentage rate, but on a small base. Heavy investment in R&D will pay off as the decade progresses.

5 months ago - Seeking Alpha

The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq...

5 months ago - Business Wire

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...

Other stocks mentioned: ADXS, ARWR
5 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framework for value-based agreements (VBAs) designed to help...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved OXLUMO™ (...

5 months ago - Business Wire

Alnylam (ALNY) gets European approval for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1 in all age groups.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorizat...

5 months ago - Business Wire

Alnylam exceeded third-quarter sales expectations, with a stronger-than-expected recovery in Onpattro and healthy Givlaari sales. Another look at the Phase I ALN-AGT study showed double-digit blood pres...

5 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim data from the ongoing Phase 1 study of ALN-AGT, a...

5 months ago - Business Wire

Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.

6 months ago - Zacks Investment Research

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatme... [Read more...]

Industry
Biotechnology
IPO Date
May 28, 2004
CEO
John Maraganore
Employees
1,453
Stock Exchange
NASDAQ
Ticker Symbol
ALNY
Full Company Profile

Financial Performance

In 2020, ALNY's revenue was $492.85 million, an increase of 124.28% compared to the previous year's $219.75 million. Losses were -$858.28 million, -3.14% less than in 2019.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is 174.89, which is an increase of 35.81% from the latest price.

Price Target
$174.89
(35.81% upside)
Analyst Consensus: Buy